Noticias de PCVX_US
Noticias del mercado
Últimas noticias sobre PCVX_US — 247 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior…
Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and…
Vaxcyte Inc. stocks have been trading up by 8.52 percent following strong clinical progress and heightened vaccine market optimism. Key Takeaways For PCVX Traders Positive Phase 3 OPUS-1 topline data for VAX-31 in adults met all key immune response goals versus current standards PCV20 and PCV21,
Vaxcyte Inc. stocks have been trading up by 8.52 percent following strong clinical progress and heightened vaccine market optimism. Key Takeaways For PCVX Traders Positive Phase 3 OPUS-1 topline data for VAX-31 in adults met all key immune response goals versus current standards PCV20 and PCV21,
Vaxcyte Inc. stocks have been trading up by 8.72 percent amid strong vaccine pipeline progress boosting investor optimism. Key Takeaways Phase 3 OPUS-1 topline data for VAX-31 beat even bullish expectations, with Jefferies seeing potential to capture a large chunk of a $3B–$6B+ adult PCV market and maintaining a $146 target. Mizuho called VAX-31’s Phase…
Second-quarter earnings per share were USD -1.97 versus USD -2.06 consensus. Vaxcyte stock costs EUR
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced the pricing of concurrent underwritten...
Vaxcyte intends to use net proceeds for VAX-31 trials, manufacturing scale-up and U.S. launch preparation; offerings are expected to close Oct. 9.
Página 3 de 13